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After primary infection, HSV-1 can reach
the central nervous systemwhere, in rare
cases, it replicates and triggers an acute
and inflammatory response resulting in
herpes simplex encephalitis (HSE).
The presence of the HSV-1 genome has
been revealed in tissues of the peripheral
and central nervous system of individuals
with no clinical signs of HSE.
In humans, levels of circulating anti-HSVHerpes simplex virus-1 (HSV-1) establishes latency preferentially in sensory
neurons of peripheral ganglia. A variety of stresses can induce recurrent
reactivations of the virus, which spreads and then actively replicates to the site
of primary infection (usually the lips or eyes). Viral particles produced following
reactivation can also reach the brain, causing a rare but severe form of diffuse
acute infection, namely herpes simplex encephalitis. Most of the time, this infec-
tion is clinically asymptomatic. However, it was recently correlated with the pro-
duction and accumulation of neuropathological biomarkers of Alzheimer’s
disease. In this review we discuss the different cellular and molecular mecha-
nisms underlying the acute and long-term damage caused by HSV-1 infection
in the brain.immunoglobulins, considered as markers
of HSV-1 reactivation, have been posi-
tively correlated with an increased risk
of Alzheimer’s disease (AD).
Experimental data show that HSV-1 in-
fection of neurons activates neurotoxic
pathways typical of AD, and repeated
HSV-1 reactivations in the brain of
infected mice produce an AD-like
phenotype.
Further studies are required to get
greater mechanistic understanding of
the causal links between recurrent
HSV-1 infections in the brain and AD as
well as to validate experimental findings
in humans.
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HSV-1 is a widely distributed neurotropic human pathogen that is transmitted mainly by intimate
contact between infected and susceptible individuals, and it causes labial, ocular, or genital infec-
tions [1]. Primary infection usually occurs during childhood: over 60% of individuals under
50 years of age are infected with HSV-1 worldwide [2]. After primary infection of epithelial
cells, the virus becomes latent in neurons of the peripheral nervous system (PNS) and can be
periodically reactivated resulting in recurrent clinical or subclinical episodes throughout life [1].
Although sympathetic neurons can be also affected, HSV-1 mainly infects sensory neurons
close to the site of primary infection [3,4], subsequently traveling retrogradely along the axon
to the cell body in the peripheral ganglia. Studies in animal models have shown that the virus
can also reach the central nervous system (CNS) [5–14] (Figures 1 and 2A). In humans, viral
replication in the brain may result in herpes simplex encephalitis (HSE) (reviewed in [15]) or
milder/asymptomatic infections eventually followed by latency [16]. A growing body of evidence
indicates that the cumulative effects of repeated 'mild' HSV-1 brain infections may result in
neuronal damage similar to that found in neurodegenerative disorders such as Alzheimer’s
disease (AD), the most common form of dementia in the elderly (Box 1) [17]. Here, we review re-
cent knowledge on the pathogenic mechanisms underlying neuronal damage caused by HSV-1
infection and discuss the effects of severe acute infection and repeated viral reactivations.
HSV-1 Replication and Latency in Neurons
HSV-1 consists of a linear double-stranded DNA genome within an icosapentahedral capsid. The
capsid is surrounded by an amorphous proteinaceous coating (the tegument) and the viral
envelope, in which multiple glycoprotein spikes are embedded. Virus binding and entry into
host cells are mediated by specific association between viral glycoproteins (gB, gC, gD, and the
gH/gL complex) and receptors located on target cells, including the herpesvirus entry mediator
(HVEM), heparan sulfate moieties, and the cell-adhesion proteins nectin-1 and nectin-2 (reviewed
in [18]). After primary replication in epithelial cells, HSV-1 enters peripheral neurons following fusionTrends in Microbiology, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.tim.2020.03.003 1
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Figure 1. Schematic Representation of Acute and Latent Herpes Simplex Virus-1 (HSV-1) Infection in Humans.
Acute infection: (A) HSV-1 virion enters the epithelial cell via envelope fusion with the plasma membrane. Tegument proteins
and the capsid containing the linear viral genome are released into the cytoplasm. (B) The capsid reaches the nucleopores by
microtubule transport and releases the viral genome into the nucleus, where (C) the genome circularizes and sequential
transcription of α, β, and γ genes begins. Arrows indicate nucleocytoplasmic traffic of viral mRNA (black) and related
proteins (red). (D) DNA replication begins upon completion of the production of α and β proteins, including viral DNA
polymerase. Viral DNA synthesis stimulates the production of γ proteins, which, in turn, participate in capsid assembly and
virion formation. (E) The newly synthesized genome is enclosed in the capsid, and the nucleocapsid buds through the
nuclear membranes, endoplasmic reticulum, and/or trans-Golgi network vesicles to form an enveloped virion. (F) Newly
formed viral particles are released. Latent infection: (G) HSV-1 capsid reaches the neuronal cell body in the sensory
ganglia and is transported to the nucleopore by retrograde axonal transport. In the nucleus, viral DNA circularizes and is
assembled with the nucleosome, causing the host cell to silence viral genome transcription (H), except for latency-
associated transcript (LAT) genes.
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Trends in Microbiologyof viral and cellular membranes, a process mediated by the interaction between gD and nectin-1
[19]. This usually occurs at the axon termini of peripheral trigeminal ganglia (TG) neurons that inner-
vate the orofacial or corneal epithelial layer. HSV-1 capsids travel to the cell body by retrograde
axonal transport, enter the ganglion neurons, and release the viral DNA into the nucleus to establish
latency [1]. The latency may be favored by inefficient transport to the neuronal cell body of the
tegument protein viral transactivator VP16, required to efficiently activate the viral lytic program,
as described below [20] (reviewed in [21]). Latent HSV-1 genomes persist in episomal forms within
the nucleus, where they can interact with promyelocytic leukemia (PML) nuclear bodies (NBs)
which are involved in the establishment of latency [22–24]. During latency, HSV-1 DNA is
chromatinized with heterochromatic histone marks, whereby only a small subset of viral genes is
expressed [25,26].
The most abundant products of viral gene expression during latency are latency-associated
transcripts (LATs), a primary 8.3/9 kb transcript and two stable introns (2.0 and 1.5 kb) derived
from rapid splicing of primary LAT [1,25,26]. In addition to LATs, latent virus produces several
microRNAs (miRNA) (see Glossary) [27,28] that act synergistically with LATs to repress viral
replication and may contribute to inhibition of apoptosis and stimulation of viral reactivation
[29]. A range of stimuli, including fever, emotional stress, hormone imbalance, UV exposure,2 Trends in Microbiology, Month 2020, Vol. xx, No. xx
Glossary
Avidity and avidity index: avidity is a
measure of the strength of antibody
binding to the antigen; the avidity index is
the percentage of antibodies bound to
the antigen after denaturation treatment.
cGAS–STING: cyclic guanosine
monophosphate (GMP)–adenosine
monophosphate (AMP) synthase
(cGAS) is a sensor of cytosolic DNA that
produces cGAMP, a secondary
messenger, to activate the adaptor
protein stimulator of interferon genes
(STING) and, in turn, to induce a type I
interferon response.
Cytokines: small proteins secreted by
different cell types (primarily T and B
lymphocytes, monocytes, leukocytes,
macrophages, microglia) to enhance
and regulate interactions and
communication among cells.
Chemokines are cytokines with
chemotactic activity.
Membrane depolarization: after
binding of signaling molecules
(e.g., neurotransmitters) to the plasma
membrane, the membrane potential
(different ionic distribution on both sides
of the plasma membrane) shifts from
negative to positive charge, modifying
membrane permeability to various ions.
microRNAs (miRNAs): small
endogenous molecules of noncoding
single-stranded RNA that bind
complementary messenger RNAs
(mRNAs) to inhibit their translation.
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Box 1. Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia: an estimated 40–50 million individuals are currently
affectedworldwide, and this number is expected to double in the next 20 years [63]. AD is characterized by the progressive
impairment of cognitive functions, particularly memory. While genetic mutations in amyloid precursor protein (APP) and
presenilin proteins account for a small percentage of AD cases [familial AD (FAD)], the majority of AD cases are sporadic
(SAD), and are thought to involve as-yet-unidentified environmental factors. There is no effective therapy for AD, and
currently available pharmacological treatments are primarily aimed at enhancing cholinergic activity, which is reduced in
AD patients, or delaying the formation of amyloid plaques in the brain (see Box 3). Several pathogenic mechanisms,
including accumulation of amyloid beta (Aβ) and phospho Tau (pTau) oligomers, oxidative stress, mitochondrial dysfunc-
tion, and neuroinflammation have been proposed to contribute to AD onset and progression. Recent epidemiological and
experimental evidence strongly support the hypothesis that microbial agents are risk factors for AD. Specifically, herpes
simplex virus type-1 (HSV-1) is gaining greater attention because of its ability to cause recurrent, life-long infection.
Trends in Microbiologytrauma, and immunosuppression, can reactivate the latent virus within infected ganglia [1]. These
factors can directly affect HSV-1-infected neurons or can act at the level of surrounding, non-
neuronal cells (e.g., satellite glia and CD8+ T cells), promoting nuclear accumulation of host
transcription factors and viral VP16 in neurons [21]. Newly synthesized VP16 may also sustain
HSV-1 reactivation in neurons [30]. Reactivation usually results in productive infection although
abortive reactivations may also occur [21,31]. In the nucleus, productive infection begins with
the sequential expression of three subsets of viral genes [immediate early (IE), early (E), and late
(L) genes] mediated by cellular RNA polymerase II. Specifically, viral transactivator VP16 induces
the initial transcription of IE genes, the products of which activate E gene expression, in turn pro-
moting transcription of L genes. Structural proteins and new viral genomes are then assembled
into capsids, which translocate to the cytoplasm, probably by budding from the inner nuclear
membrane (envelopment phase) and fusing with the outer nuclear membrane (de-envelopment
phase). Naked capsids acquire tegument and their definitive envelope (re-envelopment phase)
in the vesicles of the trans-Golgi network, and the mature virion exits the host cells near the cell
body [1] (reviewed in [32]). Alternatively, naked capsids and viral glycoproteins, or complete
virions, can travel anterogradely inside separate vesicles anchored to the microtubule scaffolding,
reaching the axonal shaft and tip in the periphery, where they are released [32]. Usually, this gives
rise to blisters, sores, or ulcers at the site of primary infection, although reactivation can be
asymptomatic, despite the shedding of newly produced infectious virus [33]. Because sensory
trigeminal neurons are pseudounipolar, new viral particles can also reach the CNS via antero-
grade transport. Specifically, one of the two branches of TG neurons projects to the trigeminal
nuclei in the brainstem, from which projections reach the thalamus and, from there, the sensory
cortex. TG neurons have therefore been proposed as a direct route for HSV-1 entry to the CNS
(reviewed in [34]). HSV-1 infection of the CNS can cause HSE, a severe inflammatory brain
disease (estimated worldwide incidence: 2.5–12 cases/million/year [35]) that causes 70%
mortality in untreated patients and up to 30%mortality combined with a high incidence of neuro-
logical sequelae in patients treated with antivirals. Primary HSV-1 infection and HSV-1 reactivation
account for one-third and two-thirds of all HSE cases, respectively (reviewed in [15]). The HSV-1
genome has been detected in postmortem brain tissue from individuals with no clinical signs of
HSE, suggesting that HSV-1 may establish latency in the CNS [36,37]. Postmortem findings in
brain tissue must be interpreted with caution, and multiple confounding factors must be taken
into account (e.g., fixation/storage time, lateralization, handling, contamination, protein/nucleic
acid degradation, impact of antemortem factors such as drug treatments and the duration ofFigure 2. Schematic Representation of Herpes Simplex Virus-1 (HSV-1) Detection in Human andMurine Brain
Areas. (A) Sagittal representation of murine brain showing the areas in which HSV-1 is detected after oral, nasal, or ocula
inoculation (indicated with colored dots) in in vivo models; related studies, detection methods, and primary site of HSV-1
inoculation are listed below. (B) Sagittal (left) and external (right) representation of human brain showing the presence o
HSV-1 DNA as detected in postmortem brains; related studies and detection methods are listed below. Colored areas are
HSV-1-positive. (See [5–14,36,37,68,69,105,115–117].)
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Trends in Microbiologyagonal status (discussed in [37,38]). However, these confounding factors are unlikely to have
influenced the aforementioned reports of HSV-1 detection, in which very strict positivity criteria
were applied. HSV-1 has also been detected both in cerebrospinal fluid (CSF) and brain tissue
taken from neurosurgery patients who showed no signs of HSV-1 infection before surgery
(HSV-1 detection in both postmortem brains and clinical samples are reviewed in [39]). Recent,
albeit controversial, in vivo findings suggest that latent HSV-1 may be directly reactivated in the
CNS. In latently infected C57BL/6N mice, HSV-1 reactivation occurred in the brainstem indepen-
dently of reactivation in the TG [11]. In the same mouse model, Doll et al. [13] reported larger
amounts of infectious virus, as detected by direct plaque assay, and a higher reactivation
frequency in the TG than in the brainstem, and suggested that the virus is reactivated in the TG
and subsequently transported to the brainstem. We detected infectious virus in several brain re-
gions (i.e., neocortex, hippocampus, and cerebellum) in BALB/c mice 4 days after labial HSV-1
inoculation, and active virus replication in the same cerebral tissues in response to a reactivation
stimulus [14]. However, whether viral reactivation in the brain occurred independently of reactiva-
tion of a latent viral reservoir in the TG remains to be clarified. In conclusion, although animal
models of infection do not perfectly reflect HSV-1 latency and reactivation in humans, several ob-
servations in animal models, together with findings in postmortem human brain samples, indicate
that the virus can reach the brain (Figure 2). Further studies are required to clarify how and when
the virus reaches and replicates in the human brain, and to unravel the role of host-related factors
(e.g., sex, genetic background, immune response) in determining the severity and outcome
of infection.
Acute HSV-1 Infection of the CNS: Focus on HSE
HSV-1 replication in the brain and the consequent activation of host immune responses may re-
sult in HSE [15,40]. As demonstrated in vivo in experimental models [41], acute HSV-1 infection of
the brain induces an influx of peripheral lymphocytes to help virus clearance. Circulating lympho-
cytes are recruited by CNS-resident cells (e.g., astrocytes andmicroglia) (Box 2) that secrete spe-
cific cytokines and chemokines in response to virus infection [42]. Specific pattern-recognition
receptors (PRRs) on microglia and astrocytes (Figure 3, upper panel) recognize invariant HSV-1
structures, such as proteins or nucleic acids, known as pathogen-associated molecular patterns
(PAMPs). Toll-like receptors (TLRs) are PRRs that play key roles in extracellular (TLR2, TLR4) and
intracellular (TLR3, TLR9) HSV-1 detection [43–45]. Binding of HSV-1 PAMPs to TLRs activates
intracellular signaling mediated by nuclear factor κB (NF-κB) or interferon regulatory factors (IRFs)
[46]. Activated NF-κB and IRFs, alone or synergistically, increase gene transcription of proinflam-
matory cytokines and chemokines, including type-1 interferon (IFN), TNF-α, IL-1β, IL-6, IL-12B,
CXCL1, and CXCL2 in mice [47], and TNF-α, IL-1, RANTES, and IP-10 in humans [48]. MicroglialBox 2. Microglia
The term 'glia', from the Greek word glìa meaning glue, refers to a variety of types of brain cell (astrocytes, oligodendro-
cytes, and microglia) playing a critical role in neuronal function and dysfunction. Microglia are macrophage-like cells that
reside within the parenchyma of the nervous system. They differ from other glial cells in that they are not derived from
ectodermal tissue, but from yolk-sac progenitors during embryonic hematopoiesis, and therefore belong to the myeloid
lineage. Microglia primarily mediate the clearance of neurotoxic molecules, such as cellular debris, dying cells, and
misfolded proteins, preserve brain homeostasis, and enhance the innate immune response in the nervous system. Microglia
exist in a resting state under physiological conditions, and undergo two forms of activation: (i) the M1 state, characterized by
the production and secretion of proinflammatory cytokines (IL-1β, IL-6, IL-12, TNF-α, CCL2) and reactive oxygen and nitro-
gen species (ROS and RNS, respectively); and (ii) the M2 state, during which microglia produce anti-inflammatory cytokines
(IL-10, TGF-β), growth factors (IGF-1, FGF, NGF), and the neurotrophin brain-derived neurotrophic factor (BDNF) [111]. In
Alzheimer’s disease (AD), amyloid beta (Aβ) binds to pattern-recognition receptors (PRRs) on the microglial surface, activat-
ing resting microglia. These microglia, in turn, release cytokines to enhance phagocytosis and Aβ uptake and clearance, in-
hibit inflammatory processes, and promote tissue repair. Long-term activation of microglia gives rise to neuroinflammation
causing synaptic dysfunction and neurotoxicity that significantly contribute to neurodegeneration.
Trends in Microbiology, Month 2020, Vol. xx, No. xx 5
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Trends in MicrobiologyTLR3, which is located in endosomal compartments, recognizes both cytosolic HSV-1 dsDNA
[49] and an HSV-1 dsRNA intermediate [50], and its signaling cascade converges on IRF-3/7
and NF-κB, which subsequently induce the production of type-I IFNs and IL-1β, respectively
[51]. Microglial type-I IFN, which is crucial for brain clearance of HSV-1 [52], is also induced in a
cGAS–STING-dependent manner upon HSV-1 infection, as demonstrated in a study in which
primary cells isolated from the brains of cGAS- or STING-deficient mice were infected with
HSV-1 [53]. These mice showed increased susceptibility to HSE and concomitant impairment
of type-I IFN expression in the CNS.
TLR2, which is expressed on the plasma membrane of microglia and astrocytes, binds lipoprotein
components of HSV-1, including glycoproteins gH/gL and gB [54], and induces the transcription of
multiple cytokines, including IL-6, and MCP-1, as demonstrated in analyses of HSV-1-infected
TLR2 knockout mice [43], which have a lower mortality rate than HSV-1-infected wild-type mice.
Thus, while the innate immune response is essential to suppress HSV-1 infection, its redundant
and exacerbated activation may be detrimental, contributing to HSE pathogenesis. Furthermore,
HSV-1-infected microglial cells produce reactive oxygen species (ROS) via a TLR2-dependent
mechanism, and ROS-mediated mechanisms exacerbate disease progression [55]. The strong
inflammatory response to HSV-1 infection in the brain is also associated with increased expression
of inducible nitric oxide (NO) synthase (iNOS) enzyme, leading to release of cytotoxic NO [56].
Astrocytes upregulate iNOS in response to elevated levels of proinflammatory cytokines during
CNS injury [57], but it remains unclear whether this also occurs during HSE. Evidence suggests
that microglial cells are the main source of iNOS produced during HSE, and that increased iNOS
activity (i.e., increased NO production) enhances the expression of the antioxidant enzyme heme
oxygenase-1 (HO-1) in an attempt to restore oxidative balance and attenuate CNS damage [58].
In conclusion, the delicate balance between an effective antiviral/innate response resulting in viral
clearance and a strong inflammatory reaction across multiple brain areas distinguishes acute
HSE from a mild 'self-limiting' infection. Several factors may influence this balance, including viral
load, immune and general health status, and age. Further studies will be needed to better under-
stand how virus–host relationships affect the severity of infection and its outcomes in the brain.
Recurrent HSV-1 Infection in the CNS: Focus on Long-term Damage
Epidemiological and experimental findings from the past 20 years implicate repeated HSV-1 re-
activation in the pathogenesis of amnestic mild cognitive impairment (aMCI) and AD (reviewed
in [59]). aMCI results in memory deficits that do not impair normal daily activities [60,61], and
may be prodromal to AD [62], that is a progressive neurodegenerative disease characterized
by irreversible memory loss, cognitive decline, and deterioration of emotional control, daily
routines, and social function [63]. AD and aMCI patients show alterations in certain brain areas,Figure 3. Schematic Representation of the Mechanisms Underlying Acute [Herpes Simplex Encephalitis
(HSE)] and Long-term Central Nervous System (CNS) Damage Caused by Herpes Simplex Virus-1 (HSV-1)
Upper panel: HSE. Toll-like receptors (TLRs) on astrocytes (pink) and microglia (green) recognize HSV-1 pathogen-
associated molecular patterns (PAMPs), to which they bind, inducing the production of specific cytokines and chemokines
through activation of intracellular signaling pathways mediated by NF-κB or interferon (IFN) regulatory factors (IRFs). Type
IFN is also induced upon recognition of viral nucleotides by the microglial cGAS–STING axis. PAMP recognition also
induces the expression of the enzyme inducible nitric oxide (NO) synthase (iNOS) and production of reactive oxygen
species (ROS) in glial cells, resulting in massive inflammation. Lower panel: long-term damage caused by recurrent HSV-1
infection. Neuronal HSV-1 infection triggers intracellular Ca2+ signaling and induces glycogen synthase kinase 3 (GSK3
activation and consequent production of Aβ peptides (Aβs) and several amyloid precursor protein (APP) fragments
including APP intracellular domain (AICD). AICD may act as a transcriptional regulator at the promoter of GSK3, promoting
expression and activation of GSK3, which is also involved in Tau hyperphosphorylation. Aβs accumulate both inside and
outside neurons where they form plaques. Recognition of Aβ oligomers by TLR2 on the surface of glial cells induces
localized neuroinflammation through the release of proinflammatory cytokines, ROS, and NOS, and the consequen
decrease in Aβ phagocytosis.
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Trends in Microbiologyincluding the entorhinal cortex and hippocampus [64], which exhibit distinctive histological fea-
tures (Box 3) including extraneuronal insoluble aggregates (plaques) of amyloid beta (Aβ) peptides
and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated Tau protein (pTau) [65]. Ball
[66,67] first proposed a role for cerebral HSV-1 infection in AD pathogenesis, based on the poten-
tial capability of HSV-1 to move from TG to the brain regions most affected in AD. Subsequent
postmortem studies of small patient cohorts detected latent HSV-l in brain samples from both
AD patients and healthy elderly controls [68], and showed a correlation in AD patients between
HSV-1 infection and the ε4 allele of apolipoprotein E (ApoE-ε4) [69], a known risk factor for AD
[70] that is associated with the incidence of recurrent herpes labialis in humans [69] and with
increased HSV-1 neuroinvasiveness in mice [71]. A recent molecular and bioinformatics analysis
of postmortem brain samples from four independent cohorts of AD and control patients reported
increased expression of human herpesvirus (HHV)-6A and HHV-7, as well as HSV-1, in AD
patients versus controls, and a correlation between increased herpesvirus expression and AD-
related changes in gene expression [72]. Conversely, RNA and DNA sequencing analyses of
AD brain repositories revealed no association between AD and HHV-6, and did not examine
associations with HSV-1 [73]. These conflicting findings emphasize the need for parallel multi-
disciplinary approaches to investigate the potential microbial component of AD pathogenesis.
Two studies [74,75] of small sample populations (19 versus 21, and 33 versus 28 AD patients
and healthy controls, respectively) reported no association between AD and levels of anti-HSV
immunoglobulin G (IgG), which were similar to [74] or higher than those in AD patient samples
[75]. In 2008, a study evaluated levels of anti-HSV-1 immunoglobulin M (IgM), considered to be
a marker of primary HSV-1 infection and/or viral reactivation, in a cohort of over 500 elderly indi-
viduals that were initially dementia-free [76]. After 14 years of follow up, individuals positive for
anti-HSV-1 IgM had a significantly higher risk of developing AD, suggesting a strong correlation
between HSV-1 reactivation and AD incidence. These findings were later replicated in a larger co-
hort [77]. Kobayashi and coworkers reported a correlation between repeated HSV-1 reactivation
and increased anti-HSV-1 IgG avidity [78], and a higher anti-HSV-1 IgG avidity index in aMCI
patients than in AD patients and healthy subjects. These correlative findings do not demonstrateBox 3. Molecular Hallmarks of Alzheimer’s Disease
The main histopathological lesions observed in the brains of Alzheimer’s disease (AD) patients are amyloid plaques and
neurofibrillary tangles (NFTs). Amyloid plaques are formed by the accumulation of insoluble aggregates of amyloid beta
peptides (Aβs) that are produced by amyloidogenic cleavage of amyloid precursor protein (APP) [65]. Full-length APP is
a transmembrane protein that is physiologically processed by multiple secretases. In the non-amyloidogenic pathway,
α-secretase cleaves APP within the Aβ peptide region. The C-terminal fragment, which remains associated to the
membrane, can be further processed by γ-secretase. In the amyloidogenic pathway, subsequent processing by β- and
γ-secretases yields Aβ peptides (mainly Aβ40 and Aβ42, consisting of 40 or 42 amino acids, respectively). Aβ production
occurs under physiological conditions and may support synaptic function [112]. However, abnormal increases in Aβ levels
caused by imbalanced production/clearance results in the formation of Aβ aggregates, with corresponding neurotoxic
effects. These aggregate forms include Aβ oligomers and fibrils, and, ultimately, insoluble senile plaques. Intracellular
and extracellular accumulation of Aβ oligomers correlates strongly with synaptic and memory deficits caused by impair-
ment of critical components of the synaptic machinery [112]. Aβ oligomers also activate microglia and astrocytes, stimu-
lating cytokine and ROS production and triggering neuroinflammation and neuronal damage.
NFTs are formed by the aggregation of the cytoskeletal protein Tau. In healthy individuals Tau binds and stabilizes
microtubules, mediates axonal transport, and modulates synaptic structure and function. Tau undergoes several post-
translational modifications (e.g., phosphorylation, glycosylation, nitration, methylation, proteolytic cleavage). In neurode-
generative diseases, especially AD, Tau hyperphosphorylation leads to conformational changes, impairing the protein’s
ability to associate with microtubules [113]. Many kinases, including GSK3β, CDK5, MAPK, JNK, and p38, finely regulate
this process. Once soluble, Tau undergoes dimerization and then self-associates into oligomers, filaments [better known
as paired helical filaments (PHFs)], and ultimately organized structures such as NFTs. Tau alterations are a characteristic of
many neurodegenerative diseases, collectively known as tauopathies. A large body of evidence suggests that Aβ and
phospho Tau (pTau) oligomers are critical determinants of AD pathophysiology [114], although the relative contribution
of each to AD pathogenesis, their interplay, and the complex factors underlying their production and accumulation in
the brain are only partly understood.
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HSV-1 reactivation may contribute to the transition between health and aMCI, or between
aMCI and AD. Specific anti-HSV-1 immune responses (as determined by anti-HSV-1 IgG titer/
avidity index) may play a protective role in early-stage AD [79,80], and protect against progression
from aMCI to AD [81]. In addition, two recent studies exploring anti-HSV-1 immunoglobulins in
aged individuals provide evidence supporting the synergy between ApoE-ε4 and HSV-1 in
increasing the risk of AD [82,83]. However, further studies will be required to replicate these
findings in larger patient cohorts and to clarify the role of specific anti-HSV-1 IgG in AD onset.
In the past two decades, numerous research groups, including ours, have worked to unravel the
cellular and molecular mechanisms underlying the potential role of HSV-1 infection in AD patho-
genesis (reviewed in [59]). Initial evidence supporting this hypothesis came from a study of human
neuroblastoma cells, in which HSV-1 infection induced cleavage of amyloid precursor protein
(APP) and subsequent production of a C-terminal APP fragment containing the Aβ sequence
[84]. Another study attributed the formation and accumulation of Aβ to HSV-1-induced upregu-
lation of secretases, the enzymes implicated in Aβ production via APP cleavage [85]. Piacentini
and coworkers reported that HSV-1 binding to the plasma membrane of rat primary cortical
neurons induced membrane depolarization and consequent intracellular Ca2+ signaling [86],
mimicking observations in cultured neurons from a triple transgenic (3×Tg-AD) mouse model of
AD [87]. Intracellular Ca2+ signals, in turn, were shown to elicit APP phosphorylation at Thr668
via glycogen synthase kinase 3 (GSK3) activation and consequent amyloidogenic cleavage of
APP [86,88]. Interestingly, in vitro studies have shown that GSK3, which is markedly activated
in AD brains [89], contributes to Tau hyperphosphorylation during HSV-1 infection [90], and
to the Aβ-mediated decrease in expression of the presynaptic proteins synapsin-1 and
synaptophysin [88]. Furthermore, HSV-1-induced processing of APP leads to the production of
Aβs and of APP intracellular domain (AICD) [91,92], a C-terminal fragment of APP that regulates
the transcription of several genes implicated in AD [93]. Specifically, both intracellular and extra-
cellular Aβ monomers and oligomers have been detected in HSV-1-infected human neuroblas-
toma cells and rat primary cortical neurons [91]. AICD is reported to bind the promoter region
of the GSK3 and neprilysin (NEP) genes, the latter of which encodes an enzyme involved in Aβ
clearance [94], inducing their transcription during the early phases of HSV-1 infection [92].
Santana and colleagues [95] showed that HSV-1 infection induced Aβ accumulation by impairing
the autophagymachinery in human neuroblastoma cells. Together, these findings clearly demon-
strate that HSV-1 infection of neurons activates several distinct mechanisms that can cause
Aβ accumulation and consequent neurotoxic events. Interestingly, Aβs, to which antimicrobial
activity has been ascribed [96,97], have been shown to limit HSV-1 infection both in vitro
[98,99] and in vivo [100]. In their study in 5×FAD mice (a transgenic mouse model of AD that
overexpresses human Aβ [101]) subjected to hippocampal HSV-1 inoculation, Eimer and col-
leagues demonstrated improved survival compared with wild-type littermates, and accelerated
Aβ deposition in the brain following viral infection [100]. The authors suggested that the produc-
tion and aggregation of neurotoxic peptides could counteract viral infection by sequestering the
virus. However, all mice succumbed to acute lethal infection after 125 h. A very recent study
showed that HSV-1 accelerates Aβ aggregation kinetics in vitro and proposed that this occurs
via surface-assisted heterogeneous nucleation of the peptide [102]. The authors also observed
increased Aβ levels in the brains of 3-month-old 5×FAD mice 48 h after intracranial HSV-1
inoculation compared with uninfected mice, confirming the virus’s ability to catalyze Aβ formation
and accelerate the pathogenesis of AD. Based on these findings, it is tempting to speculate that
the protective and pathogenic actions of Aβ could reflect a Janus behavior of the protein: an initial
protective (i.e., antimicrobial) effect may transition to a neurotoxic effect due to overproduction
and accumulation of Aβ induced by repeated HSV-1 reactivations in the brain.Trends in Microbiology, Month 2020, Vol. xx, No. xx 9
Outstanding Questions
Is periodic reactivation of HSV-1 in
humans accompanied by spreading
and replication of the virus in the brain?
To what extent do the different
outcomes of HSV-1 brain infection
(herpes simplex encephalitis versus
mild or asymptomatic infection) depend
on viral load, host antiviral response,
and/or the host’s genetic andmetabolic
characteristics?
Repeated reactivation of HSV-1 causes
long-term damage in the mouse brain.
Is this effect dependent on the number
or frequency of reactivations, and/or
the impairment of host ability to coun-
teract the accumulation of neurotoxic
damage?
What is the role of glia in (i) controlling
HSV-1 infection, and (ii) exacerbating
neurodegenerative damage?
Could antiviral treatments or
preventive vaccines effectively block
the neurodegenerative processes
triggered by repeated HSV-1
reactivation?
Trends in MicrobiologyFurther supporting the neurodegenerative potential of HSV-1, HSV-1 infection in neurons in vitro
induces Tau hyperphosphorylation [103] and results in DNA damage by impairing DNA repair
mechanisms [104]. Some of the aforementioned findings have been validated in in vivo studies,
although most were performed using animal models of acute HSV-1 infection [105–107]. Based
on previous models of in vivo HSV-1 infection and reactivation [108], we induced up to seven
HSV-1 reactivations at 1-month intervals in mice and showed that recurrent HSV-1 brain infection
leads to progressive accumulation of several molecular biomarkers of AD, including Aβ,
hyperphosphorylated Tau, and the proinflammatory cytokines IL-6 and IL-1β [14]. Remarkably,
accumulation of these markers was associated with impaired adult hippocampal neurogenesis
and correlated with an increasing, irreversible cognitive decline in HSV-1-infected mice subjected
tomultiple virus reactivations [14,109]. Clearly, this model does not perfectly mirror HSV-1 infection
in humans, in which viral reactivation varies both in frequency and severity. Moreover, whether each
instance of reactivation leads to active viral replication in the brain remains unknown.
A recent retrospective cohort study [110] reported a 2.56-fold increase in the risk of developing de-
mentia, including AD, over a 10-year follow-up period in Taiwanese HSV patients over 50 years of
age compared with a matched control group. The study examined the incidence of dementia dur-
ing the period 2001–2010 in 8362 subjects newly diagnosed with HSV-1 in 2000, and in 25 086
matched subjects who had no history of HSV infection during that same year. Moreover, the inci-
dence of dementia was lower in HSV-infected patients who had been treated with anti-herpes
agents (n = 7215) than those who had not (n = 1147). Althoughmerely correlative, the findings sup-
port the view that virus reactivation and replication in the brain may contribute to the incidence of
dementia, including AD. To date, no prospective longitudinal cohort study has investigated the
link between HSV-1 reactivation (symptomatic and asymptomatic) and the presence of AD
biomarkers.
In summary, despite a number of conflicting results, there is a growing body of evidence
supporting that repeated, mild HSV-1-infections in the brain may contribute to the onset and/or
progression of neurodegeneration (Figure 3, lower panel).
Concluding Remarks
Evidence from epidemiological and experimental studies suggests a causal link between recur-
rent HSV-1 infection and neurodegenerative processes typical of AD, although further studies
are required to validate this correlation in humans. The data reviewed here highlight several key
challenges for future research: (i) to identify AD biomarkers in patients with recurring HSV-1 infec-
tion; (ii) to understand the virus- and host-related factors (e.g., viral yield, genetic/metabolic fea-
tures, concurrent diseases or infections) involved in determining the frequency and extent of
virus spread to the brain, and their correlation with neurodegenerative damage; and (iii) to identify
novel strategies to limit virus reactivation and diffusion to the brain, and evaluate their potential to
prevent neurodegenerative damage (see Outstanding Questions).
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